Academic Journal
Q1Journal of Cystic Fibrosis
About Journal of Cystic Fibrosis
Journal of Cystic Fibrosis is a scholarly journal published by Elsevier B.V.. SCImago 2025 lists it in Q1, with an SJR of 1.908 and H-index of 103.
Coverage: 2002-2026. Research categories: Pediatrics, Perinatology and Child Health (Q1); Pulmonary and Respiratory Medicine (Q1).
Source-backed journal facts
Topics in published research
Cystic Fibrosis Research Advances; Neonatal Respiratory Health Research; Pediatric health and respiratory diseases; Inhalation and Respiratory Drug Delivery; Tracheal and airway disorders; Child Nutrition and Feeding Issues.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Reported open-access list prices
4,370.00 USD; 4,090.00 EUR; 3,500.00 GBP; 542,010.00 JPY
APC list prices reported by OpenAlex, which obtains this information from DOAJ. Confirm current charges, taxes, waivers and eligibility with the publisher; this is not a fee quotation.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Assessing the impact of elexacaftor/tezacaftor/ivacaftor on work productivity and activity impairment in people living with cystic fibrosis in Canada
Grace G Kim, Taryn Wong, Jonathan Rayment, Lara Bilodeau et al.
2026-09 · DOI: 10.1016/j.jcf.2026.09.005Poster: 189Reverse engineering of pathological mucus of muco-obstructive diseases
R. Freeman
2026-09 · DOI: 10.1016/j.jcf.2026.07.220Poster: 250Rational design of a synthetic miniaturized CFTR promoter for gene and cell therapy applications
J. Campos-Gomez, T. Huang, H. Chen, K. Vijaykumar et al.
2026-09 · DOI: 10.1016/j.jcf.2026.07.281Poster: 304Prenatal CFTR modulator exposure: from pregnancy to infancy and beyond
S. Szentpetery
2026-09 · DOI: 10.1016/j.jcf.2026.07.335Poster: 647Geographic variation in ambient particulate matter exposure among Medicaid-enrolled people with cystic fibrosis initiating elexacaftor/tezacaftor/ivacaftor
L. Gomez, C. Esther, S. Setoguchi
2026-09 · DOI: 10.1016/j.jcf.2026.07.687Poster: 526Targeting CaSR to enhance CFTR function in the intestine: a novel therapeutic strategy
M. Fusagawa, S. Tas, F. Coello Carmona, O. Cil et al.
2026-09 · DOI: 10.1016/j.jcf.2026.07.556Poster: 123LCI5 as a trial endpoint in cystic fibrosis
D. Funken, M. Shaw, R. Jensen, H. Grasemann et al.
2026-09 · DOI: 10.1016/j.jcf.2026.07.154Poster: 366Feasibility and acceptability of the OnTrackCF app to support CFTR modulator adherence
K. Riekert, E. McWilliams, T. Woo, A. Hager et al.
2026-09 · DOI: 10.1016/j.jcf.2026.07.397Poster: 50Susceptibility of clinical Pseudomonas aeruginosa isolates to antibiotic and bacteriophage therapies
B. Fung, A. Milesi Galdino, D. Contreras, M. Morgan et al.
2026-09 · DOI: 10.1016/j.jcf.2026.07.082Poster: 581Exhaled volatile organic compound biomarkers for pulmonary exacerbations in children with CF
D. Sanders, M. Woollam, E. Schulz, M. Thompson et al.
2026-09 · DOI: 10.1016/j.jcf.2026.07.621Poster: 215Exploring inflammation-associated cardiovascular risk in cystic fibrosis: Insights from novel biomarkers
P. Sadrieh, J. Mainz, K. Weylandt, A. Pietzner et al.
2026-09 · DOI: 10.1016/j.jcf.2026.07.246Poster: 241FcRn inhibition reduces T-cell mediated rejection in a mouse model of lung-directed AAV gene transfer
R. Clark, N. Onyene, D. Rittenhouse, M. Brimble et al.
2026-09 · DOI: 10.1016/j.jcf.2026.07.272Poster: 342Demographics and sweat chloride concentration of individuals with resolved CFTR genotypes after CF Foundation Mutation Analysis Program testing
M. Sheridan, H. Shultz-Lutwyche, K. D'Adamo, E. Ferg et al.
2026-09 · DOI: 10.1016/j.jcf.2026.07.373Poster: 539Body mass index distribution in adults with cystic fibrosis: A UK CF Registry study
J. Snowball, A. Adler, B. Shine, P. Lally et al.
2026-09 · DOI: 10.1016/j.jcf.2026.07.569Poster: 426Implementation of a pharmacist-led CFTR modulator initiation and management program utilizing expanded scope of practice authority
S. Garcia
2026-09 · DOI: 10.1016/j.jcf.2026.07.458Poster: 381The prevalence of pain and the relationship between fear of pain, pain and mental health outcomes in a pediatric cystic fibrosis population
M. Sexton, E. Lyons, E. Hanley, E. Muther et al.
2026-09 · DOI: 10.1016/j.jcf.2026.07.412Poster: 76Persistent positive cultures for Mycobacterium abscessus in cystic fibrosis does not reflect genomic divergence or enhanced virulence
T. Koch, M. Teve, V. Calado Nogueira de Moura, B. Vestal et al.
2026-09 · DOI: 10.1016/j.jcf.2026.07.108Poster: 721Increasing documentation of eye exams for children with cystic fibrosis treated with modulators
L. Burns, L. Vernon, S. Rebecca, H. Levy et al.
2026-09 · DOI: 10.1016/j.jcf.2026.07.761Poster: 732Reducing rates of quantity not sufficient sweat chloride test results through quality improvement methods
K. Rajala, S. Cey, C. Enochs, A. Filbrun et al.
2026-09 · DOI: 10.1016/j.jcf.2026.07.772Poster: 640Association between CFTR modulated sweat chloride concentrations and clinical outcomes across the CF population: Top line results from the CHEC-SC study
N. Mayer-Hamblett, D. VanDevanter, M. Jones-McCreary, C. O'Rourke et al.
2026-09 · DOI: 10.1016/j.jcf.2026.07.680Reviews
Community Reviews
Version History
September 25, 2026 at 7:12 am
September 25, 2026